NCT06788756 2025-12-16
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Moleculin Biotech, Inc.
Phase 2/3 Recruiting
Moleculin Biotech, Inc.
National Cancer Institute (NCI)